Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PDS Biotechnology Corp Director's Dealing 2022

Jan 20, 2022

34613_dirs_2022-01-20_b8903e09-a959-4a3d-aac6-eec09e9d05ea.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PDS Biotechnology Corp (PDSB)
CIK: 0001472091
Period of Report: 2022-01-19

Reporting Person: WOOD LAUREN (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-01-19 Employee Stock Option (Right to Buy) $6.28 A 88600 Acquired 2032-01-19 Common Stock (88600) Direct

Footnotes

F1: This option, representing a right to purchase a total of 88,600 shares of Common Stock, will become exercisable on January 19, 2023, with 25% vesting on that date and the remaining 75% vesting in equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date, until fully vested on January 19, 2026.